stage III chronic lymphocytic leukemia
Showing 1 - 25 of >10,000
Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia Trial in
Active, not recruiting
- Stage I Chronic Lymphocytic Leukemia
- +3 more
- Ibrutinib
- Laboratory Biomarker Analysis
-
Jacksonville, FloridaMayo Clinic in Florida
Mar 24, 2022
Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Prolymphocytic Leukemia Trial
Active, not recruiting
- Contiguous Stage II Small Lymphocytic Lymphoma
- +11 more
- MOR00208
- +2 more
-
Columbus, OhioThe Ohio State University Comprehensive Cancer Center
Feb 24, 2022
Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia Trial in
Completed
- Refractory Chronic Lymphocytic Leukemia
- +4 more
- Dasatinib
- +2 more
-
Portland, OregonOHSU Knight Cancer Institute
Mar 15, 2021
Chronic Lymphocytic Leukemia Trial in Cologne (Ibrutinib, Placebo)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Ibrutinib
- Placebo
-
Cologne, GermanyGerman CLL Study Group
Dec 16, 2021
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in
Active, not recruiting
- Accelerated Phase Chronic Myelogenous Leukemia
- +125 more
- tetanus-CMV fusion peptide vaccine
- laboratory biomarker analysis
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 28, 2022
Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor, Metastatic Lung Non-Small Cell Carcinoma Trial in Seattle
Terminated
- Hematopoietic and Lymphoid Cell Neoplasm
- +12 more
- Laboratory Biomarker Analysis
- ROR1 CAR-specific Autologous T-Lymphocytes
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 11, 2022
Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell
Active, not recruiting
- Adult Grade III Lymphomatoid Granulomatosis
- +71 more
- lenalidomide
- +8 more
-
Chicago, Illinois
- +5 more
Oct 8, 2021
Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia Trial in
Active, not recruiting
- Stage I Chronic Lymphocytic Leukemia
- +3 more
- alemtuzumab
- +2 more
-
Chicago, Illinois
- +1 more
Dec 29, 2020
Collecting Blood Samples From and Without Cancer to Evaluate
Not yet recruiting
- Acute Lymphoblastic Leukemia
- +61 more
- Questionnaire Administration
- Biospecimen Collection
- (no location specified)
Apr 12, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Scottsdale, Jacksonville, Rochester (drug, other, biological)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib
- +4 more
-
Scottsdale, Arizona
- +2 more
Jan 5, 2023
Chronic Lymphocytic Leukemia- Binet Staging System Trial in Spain (Acalabrutinib 100 MG Oral Capsule)
Recruiting
- Chronic Lymphocytic Leukemia- Binet Staging System
- Acalabrutinib 100 MG Oral Capsule
-
A Coruña, Spain
- +20 more
Jan 17, 2022
Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Indolent
Completed
- Ann Arbor Stage III Grade 1 Follicular Lymphoma
- +9 more
- Lenalidomide
- Rituximab
-
Houston, TexasM D Anderson Cancer Center
Sep 28, 2021
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial (Nemtabrutinib, Ibrutinib, Acalabrutinib)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Nemtabrutinib
- +2 more
- (no location specified)
Nov 22, 2023
Chronic Lymphocytic Leukemia Patients
Not yet recruiting
- Chronic Lymphocytic Leukemia
-
San Francisco, CaliforniaPower Life Sciences
Jun 2, 2023
Chronic Lymphocytic Leukemia Trial (Loncastuximab Tesirine)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Loncastuximab Tesirine
- (no location specified)
Jul 24, 2023
Malignant Tumors Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in
Active, not recruiting
- Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jan 20, 2023
Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Completed
- Hematopoietic/Lymphoid Cancer
- +135 more
- beclomethasone dipropionate
- +4 more
-
Hackensack, New Jersey
- +1 more
Feb 1, 2021
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Terminated
- Adult Grade III Lymphomatoid Granulomatosis
- +116 more
- brentuximab vedotin
- +2 more
-
Chicago, Illinois
- +2 more
Aug 30, 2021
Chronic Lymphocytic Leukemia Trial (Acalabrutinib, Obinutuzumab)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- (no location specified)
Jul 10, 2023
Multiple Myeloma, Chronic Lymphocytic Leukemia Trial in Durham (Myeloma Coach or CLL Coach Mobile App, Springboard Beyond Cancer
Completed
- Multiple Myeloma
- Chronic Lymphocytic Leukemia
- Myeloma Coach or CLL Coach Mobile App
- Springboard Beyond Cancer informational website
-
Durham, North CarolinaDuke University
Jun 23, 2023
Relapsed/Refractory Chronic Lymphocytic Leukemia Trial in Tianjin (GNC-035)
Not yet recruiting
- Relapsed/Refractory Chronic Lymphocytic Leukemia
-
Tianjin, Tianjin, ChinaInstitute of Hematology and Blood Diseases Hospital, Chinese Aca
Jul 13, 2023
Biomarker for Infection Risk in CLL and MM
Not yet recruiting
- Multiple Myeloma
- Chronic Lymphocytic Leukemia
- Screening
-
Boston, MassachusettsMassachusetts General Hospital Cancer Center
May 3, 2023
Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma Trial (Nemtabrutinib, Venetoclax,
Not yet recruiting
- Leukemia, Lymphocytic, Chronic, B-Cell
- +5 more
- Nemtabrutinib
- +2 more
- (no location specified)
Jul 21, 2023
Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small
Recruiting
- Relapsed or Refractory CD19+ B-cell Lymphoma
- +2 more
- TBI-2001
- +2 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Jul 26, 2023